Compare Alphabet Inc Class A (GOOGL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Novo Nordisk A/S — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Alphabet Inc Class A is far larger — about 25.6× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Novo Nordisk A/S for 116 Days on average.
| GOOGL | NVO | |
|---|---|---|
Market Cap | $4.24T | $165.31B |
Volume | 23,392,850 | 11,432,838 |
Sector | Media | Health |
52-Week High | $402.62 | $63.98 |
52-Week Low | $236.59 | $35.29 |
Typical Hold Time | 85 Days | 116 Days |
Enterprise Value | $4.13T | $179.56B |
Dividend Yield | 0.25% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, amid strong fundamental performance with Q2 2026 EPS beating expectations by 217%. The stock shows bullish technical signals with moving averages supporting upward momentum, while maintaining robust profitability metrics including 54.77% net income margin and 49.55% ROE. Recent developments include YouTube subscription price increases and AI infrastructure partnerships driving growth prospects.
With 87% analyst buy ratings and a $431.83 consensus target representing 24% upside, GOOGL presents compelling value at current levels. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and consistent earnings beats support long-term growth trajectory. The company's diversified revenue streams and AI leadership position it well for sustained outperformance.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
